

**AMENDMENTS TO THE CLAIMS**

The listing of claims provided below will replace all prior versions, and listings, of claims in the application.

**Listing of Claims:**

1-18. **(Cancelled)**

19. **(Currently Amended)** A method for prevention of chronic refractory graft rejection in a human lung transplant recipient comprising administering to the recipient, prior to the development of symptoms ~~associated with acute transplant rejection,~~ (i) an aerosolized composition comprising a therapeutic dose of cyclosporine, to thereby prevent chronic refractory graft rejection in the human lung transplant recipient.

20. **(Previously presented)** The method of claim 19, wherein the cyclosporine is administered as a dry powder in combination with a propellant.

21. **(Previously presented)** The method of claim 19, wherein the cyclosporine is dissolved in an organic solvent.

22. **(Previously presented)** The method of claim 19, 20 or 21 wherein the dose of cyclosporine is sufficient to achieve deposition levels ranging between 15 and 30 mg in a lung.

23. **(Cancelled)**

24. **(Previously Presented)** The method of claim 19, 20 or 21 wherein the aerosolized composition is co-administered with an effective amount of one or more other agent selected from the group consisting of an immunosuppressive agent and an anti-inflammatory reagent.

25-29. **(Cancelled)**

30. **(Currently Amended)** A method for prevention of chronic refractory graft rejection in a non-lung transplant recipient comprising administering to the non-lung transplant recipient prior to the development of symptoms ~~associated with acute transplant rejection~~, an aerosolized composition comprising a dose of cyclosporine dissolved in an organic solvent, in an amount effective to prevent graft rejection, thereby preventing chronic refractory graft rejection in the non-lung transplant recipient.

31. **(Currently Amended)** A method for prevention of chronic refractory graft rejection in a non-lung transplant recipient comprising administering to the non-lung transplant recipient, prior to the development of symptoms ~~associated with acute transplant rejection~~, an aerosolized composition comprising :

(i) a dose of cyclosporine in dry powder form in an amount effective to prevent graft rejection; and

(ii) a propellant,

thereby preventing chronic refractory graft rejection in the non-lung transplant recipient.

32-48. **(Cancelled)**

49. **(Previously Presented)** The method of claim 19, wherein the first administration occurs within 31 days of transplantation.

50. **(Previously Presented)** The method of claim 49, wherein the first administration occurs within 10 days of transplantation.

51. **(Previously Presented)** The method of claim 30, wherein the first administration occurs within 31 days of transplantation.
52. **(Previously Presented)** The method of claim 51, wherein the first administration occurs within 10 days of transplantation.
53. **(Previously Presented)** The method of claim 31, wherein the first administration occurs within 31 days of transplantation.
54. **(Previously Presented)** The method of claim 53, wherein the first administration occurs within 10 days of transplantation.